Home Newsfeeds HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Maintains $11 Price Target

HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Maintains $11 Price Target

HC Wainwright & Co. analyst Yi Chen reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Buy and maintains $11 price target.

March 7, 2023

1 minute read

HC Wainwright & Co. analyst Yi Chen reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Buy and maintains $11 price target.

Key Apple Supplier Foxconn’s Chairman Holds Talks With Sharp Employees Amid Financial Struggles: ‘I Hope We Will Overcome…’

July 6, 3:39 AM

Liu Young Way, the Chairman of Hon Hai Precision Manufacturing Company Limited (OTC:HNHPF), better known as Foxconn, addressed…

October 27, 11:37 AM

AerCap Holdings N.V. (NYSE: AER) reported third-quarter FY23 total lease revenue growth of 7% year-on-year to $1.701 billion, missing the

July 25, 6:15 AM

Full Year Expectation Capacity (ASMs) % change versus 2022 Up 11% to 13% Total revenue % change versus

July 12, 9:17 AM

JMP Securities analyst Devin Ryan maintains Stifel Financial (NYSE:SF) with a Market Outperform and lowers the price target from $103 to $100.